GlassScriptPhysician profile
Ian Adam
NPI 1679748537
$2,119.92
in general payments reported to CMS, 2019-2025
16 companies · $95.50 in 2025
The $95.50 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $422 · 2021: $290 · 2022: $437 · 2023: $157 · 2024: $303 · 2025: $95.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $555.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $799.78 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $236.02 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $219.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $190.32 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $167.35 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.07 | 2019-2024 | Jardiance |
| Vanda Pharmaceuticals INC. | $106.23 | 2021-2022 | |
| Lilly USA, LLC | $82.56 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $31.19 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $29.57 | 2025 | Eterna |
| Pfizer INC. | $26.43 | 2022-2023 | |
| Amarin Pharma, INC. | $23.70 | 2019 | |
| Phathom Pharmaceuticals, INC. | $23.27 | 2024 | Voquezna |
| Edwards Lifesciences Corporation | $16.38 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Echosens North America, INC. | $14.92 | 2025 | Fibroscan |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $13.38 | 2024 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Adam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.